NCT Number: NCT00456053
A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin
The purpose of this study is to test the safety and efficacy of FG-2216 in the treatment of patients with renal anemia who are not receiving erythropoietin and who are not on dialysis.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Research Site, Tucson, Arizona, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Stage 3 or 4 chronic kidney disease
- appropriate hemoglobin levels
Exclusion criteria
- Neovascular age related macular degeneration requiring treatment
- Macular edema or proliferative retinopathy in diabetic subjects, requiring treatment
- Any history of malignancy
- Therapy with recombinant erythropoietin or red blood cell transfusion within 4 weeks
- Renal Transplant
Treatment and study plan
Primary outcomes
-
Hemoglobin (Hb) response
Secondary outcomes
-
Attainment of Hb target range (11-13)
-
Duration of maintenance of Hb in target range (11-13)
-
Safety
Sponsors and collaborators
Lead sponsor
Kyntra Bio
Industry
Registry information
Important dates
- Study start
- 2005
- Study completion
- 2007
- First posted
- Apr 4, 2007
- Registry last updated
- Nov 6, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)
NCT01306409
Anemia, Female Urogenital Diseases
Basel, Canton of Basel-City, Switzerland
View Trial DetailsFerric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
NCT05085275
Anemia, Anemia, Hypochromic
Pine Bluff, Arkansas, United States
View Trial DetailsPost-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
NCT04408820
Renal Anemia
Aichi, Japan
View Trial DetailsHEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
NCT04925661
Chronic Disease, Chronic Kidney Diseases
Guangzhou, China
View Trial Details